<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086744</url>
  </required_header>
  <id_info>
    <org_study_id>CLNP023L12201</org_study_id>
    <secondary_id>2021-002039-40</secondary_id>
    <nct_id>NCT05086744</nct_id>
  </id_info>
  <brief_title>Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders</brief_title>
  <official_title>An Open-label, Multi-center, Phase 2 Basket Study to Assess Efficacy, Safety and Pharmacokinetics of Iptacopan (LNP023) in Participants With Autoimmune Benign Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy and safety of iptacopan in&#xD;
      participants with autoimmune benign hematological disorders such as primary immune&#xD;
      thrombocytopenia and primary cold agglutinin disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">October 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a basket study with different Cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Cohort 1: Ability of iptacopan to induce a clinically meaningful increase in platelet count in participants with primary ITP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin levels</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Cohort 2: Ability of iptacopan to induce a clinically meaningful increase in hemoglobin levels in participants with primary CAD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Time to first response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Time to first response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Magnitude of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Magnitude of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who use rescue therapy</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Need for rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase (LDH)</measure>
    <time_frame>Screening, Day 15, Day 29, Day 85, Day 113</time_frame>
    <description>Cohort 2 (CAD) only: Effect of iptacopan on relevant disease biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total billirubin</measure>
    <time_frame>Screening, Day 15, Day 29, Day 85, Day 113</time_frame>
    <description>Cohort 2 (CAD) only: Effect of iptacopan on relevant disease biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocytes count</measure>
    <time_frame>Screening, Baseline, Day 1, Day 15, Day 29, Day 85, Day 99, Day 113</time_frame>
    <description>Cohort 2 (CAD) only: Effect of iptacopan on relevant disease biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haptoglobin</measure>
    <time_frame>Screening, Day 15, Day 29, Day 85, Day 113</time_frame>
    <description>Cohort 2 (CAD) only: Effect of iptacopan on relevant disease biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Cmax</measure>
    <time_frame>Day 15 and Day 57: 0 hours, 0.5 hours, 1 hour, 2 hours, 4 hours and 6 hours</time_frame>
    <description>Pharmacokinetics (PK) of iptacopan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmcokinetic parameter: AUCtau</measure>
    <time_frame>Day 15 and Day 57: 0 hours, 0.5 hours, 1 hour, 2 hours, 4 hours and 6 hours</time_frame>
    <description>Pharmacokinetics (PK) of iptacopan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmcokinetic parameter: AUClast</measure>
    <time_frame>Day 15 and Day 57: 0 hours, 0.5 hours, 1 hour, 2 hours, 4 hours and 6 hours</time_frame>
    <description>Pharmacokinetics (PK) of iptacopan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmcokinetic parameter: Ctrough</measure>
    <time_frame>Day 15, Day 29 and Day 57: 0 hours/predose</time_frame>
    <description>Pharmacokinetics (PK) of iptacopan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmcokinetic parameter: Tmax</measure>
    <time_frame>Day 15 and Day 57: 0 hours, 0.5 hours, 1 hour, 2 hours, 4 hours and 6 hours</time_frame>
    <description>Pharmacokinetics (PK) of iptacopan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>Up to end of study (Day 757) in Part B</time_frame>
    <description>Safety and tolerability of iptacopan in participants with autoimmune benign hematological disorders</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Immune Thrombocytopenia (ITP)</condition>
  <condition>Cold Agglutinin Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Iptacopan 200 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iptacopan 200 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iptacopan</intervention_name>
    <description>Iptacopan 200 mg BID</description>
    <arm_group_label>Iptacopan 200 mg BID</arm_group_label>
    <other_name>Generic name: iptacopan</other_name>
    <other_name>Investigational new drug</other_name>
    <other_name>company code: LNP023</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Cohorts:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections is&#xD;
             required and vaccination against Haemophilus influenzae infection is recommended prior&#xD;
             to the start of treatment.&#xD;
&#xD;
          -  Weight of at least 35 kg&#xD;
&#xD;
        Cohort 1 specific inclusion criteria:&#xD;
&#xD;
          -  Participants with a diagnosis of persistent or chronic primary ITP&#xD;
&#xD;
          -  Participants must have received at least 1 prior line of ITP-directed therapy&#xD;
&#xD;
          -  Sustained thrombocytopenia&#xD;
&#xD;
        Cohort 2 specific inclusion criteria:&#xD;
&#xD;
          -  Participants with a diagnosis of primary CAD&#xD;
&#xD;
          -  Participants must have received at least 1 prior line of CAD-directed therapy&#xD;
&#xD;
          -  Laboratory evidence of ongoing hemolysis&#xD;
&#xD;
          -  Sustained anemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All cohorts:&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives&#xD;
             of enrollment, or within 30 days, whichever is longer; or longer if required by local&#xD;
             regulations&#xD;
&#xD;
          -  Past or concomitant use of medications prohibited by the protocol&#xD;
&#xD;
          -  Known or suspected hereditary or acquired complement deficiency&#xD;
&#xD;
          -  History of primary or secondary immunodeficiency, including a positive HIV test result&#xD;
&#xD;
          -  Chronic infection with Hepatitis B or C virus&#xD;
&#xD;
          -  History of recurrent invasive infections caused by encapsulated organisms, including&#xD;
             Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae&#xD;
&#xD;
          -  Presence or suspicion of any active infection within 14 days prior to first study drug&#xD;
             administration.&#xD;
&#xD;
          -  Any medical condition deemed likely to interfere with the participant's participation&#xD;
             in the study&#xD;
&#xD;
          -  Any malignant disease diagnosed within the past 5 years, with the exception of&#xD;
             localized non-melanoma skin cancer, in situ cervical cancer, or, for CAD, a low-grade&#xD;
             lymphoproliferative disorder.&#xD;
&#xD;
          -  History of bone marrow/hematopoietic stem cell or solid organ transplantation.&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using effective methods of contraception during&#xD;
             dosing of investigational drug and for 1 week after last iptacopan dose&#xD;
&#xD;
          -  Active severe bleeding or history of intracranial hemorrhage.&#xD;
&#xD;
          -  Liver disease, or liver injury as indicated by abnormal liver function tests.&#xD;
&#xD;
          -  Severe concurrent comorbidities of unstable medical conditions.&#xD;
&#xD;
        Cohort 1 specific exclusion criteria:&#xD;
&#xD;
          -  Secondary ITP, as may arise in the setting of certain autoimmune disorders,&#xD;
             immunodeficiency syndromes, infections, malignancies, and drug treatments&#xD;
&#xD;
          -  No ITP-directed background therapy permitted, with the exception of a thrombopoietin&#xD;
             receptor agonist or low-dose corticosteroid, as long as stable dosage for at least 4&#xD;
             weeks prior to baseline&#xD;
&#xD;
          -  Abnormal coagulation screening labs&#xD;
&#xD;
        Cohort 2 specific exclusion criteria:&#xD;
&#xD;
          -  Secondary cold agglutinin syndrome, as may arise in the setting of certain infections,&#xD;
             autoimmune disorders, and malignancies (with the exception of a low-grade&#xD;
             lymphoproliferative disorder)&#xD;
&#xD;
          -  No CAD-directed background therapy permitted&#xD;
&#xD;
        Additional protocol-defined inclusion / exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from applicable studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

